Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Molecules (Basel, Switzerland)|September 10, 2021
Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist-Neurokinin Antagonist PeptidomimeticsCharlène Gadais, Justyna Piekielna-Ciesielska, Jolien De Neve, et al.
RSC Medicinal Chemistry|July 5, 2021
Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factorsJolien De Neve, Thomas M A Barlow, Dirk Tourwé, et al.
Molecules (Basel, Switzerland)|June 2, 2021
Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular DockingMaria Dumitrascuta, Marcel Bermudez, Olga Trovato, et al.
Pharmacological Research|September 22, 2024
Multitarget ligands that comprise opioid/nonopioid pharmacophores for pain management: Current state of the scienceÉmile Breault, Michael Desgagné, Jolien De Neve, et al.
The Journal of Organic Chemistry|October 30, 2025
Deploying Pictet-Spengler Reactions to Access Constrained Aromatic Amino AcidsJolien De Neve, Bin Wang, Khadija Ngom, et al.
The Journal of Organic Chemistry|April 15, 2026
Trifluoromethylthio and Trifluoromethyl Functionalization of Endomorphin-1 Enhances its Hydrophobicity and Plasma Stability while Preserving its Affinity for the μ-Opioid ReceptorJure Gregorc, Jolien De Neve, Karine Guitot, et al.
ACS Pharmacology & Translational Science|September 19, 2024
Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid PeptidomimeticsJolien De Neve, Émile Breault, Santo Previti, et al.
Journal of Medicinal Chemistry|April 30, 2024
Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side EffectsJolien De Neve, Khadija Elhabazi, Simon Gonzalez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 12, 2026
Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivoÉmile Breault, Jolien De Neve, Amirmohammad Ranjbaran, et al.
Pageof 1